NFATC2 and sarcoma: Studies by Seligson et al. have shown that EWSR1::NFATC2 sarcoma has a lower response to Ewing sarcoma-specific chemotherapy and suggest that drugs targeting the mTOR pathway may become targeted therapies for treating this disease [32].